Navigation Links
Caspase-3 Activation - An Indicator of Apoptosis in Image-Based Assays

Introduction

The understanding of the cellular signaling processes leading to programmed cell death (apoptosis) is of utmost importance in the study of autoimmune diseases such as rheumatoid arthritis or Parkinsons and Alzheimers disease. Here, errors in the signaling cascade are believed to lead to premature apoptosis in the affected tissue. At the same time, damaged cells that do not enter the apoptotic pathway may proliferate unchecked and become a cancerous cell mass. Thus, the study of apoptosis benefits many different fields of medicine by offering multiple targets for specific drug treatment.

Caspases (cysteinyl aspartate-specific proteases) are a family of important signaling molecules with various tasks depending on subtype and organ. The activation of caspases is also a marker for cellular damage in diseases such as stroke or myocardial infarction (reviewed by Lavrik et al . 2005). Although the precise role in the initiation and progression of apoptosis is not known for all caspases, their involvement as an indicator alone and as a potential leverage point for drug treatment make them widely researched molecules.

We explored the use of the active form of caspase-3 for the detection of apoptotic events. This protease has been implicated as an effector caspase associated with the initiation of the death cascade and is therefore an important marker of the cells entry point into the apoptotic signaling pathway (Nicholson et al . 1995). Caspase-3 is activated by the upstream caspase-8 and caspase-9 and since it serves as a convergence point for different signaling pathways, it is well suited as a read-out in an apoptosis assay. Detection of active caspase-3 can be used in different cell lines or primary cells, does not require the use of transfection techniques and can be multiplexed with other probes to get an in-depth understanding of signaling events with cell-by-cell resolution. Since there have been reports that cells progressively undergo apoptosis when exposed to staurosprine over time (Jacobson et al . 1996), we investigated the time-dependence of apoptosis as measured by caspase- 3 activation. This application is also amenable for use in automated microscopes such as the BD Pathway Bioimager in a hands-off mode, making it useful for secondary screening applications or to gain an insight into apoptotic pathways using RNAi.

Methods

HeLa cells (ATCC, CCL-2, a human cervical cancer cell line) were maintained and grown in DMEM supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, and 10% fetal bovine serum. Cells were seeded in 96-well clear bottom tissue culture plates optimized for imaging applications (Cat. No. 353219) at 10,000 cells/well. After 16 hours in the incubator, staurosporine was added to the cells for 4 hours.

Staurosporine (Sigma-Aldrich, S4400) is a broad-spectrum kinase inhibitor known to activate the apoptosis pathway. To generate dose-response relationships, the drug was serially diluted in growth medium and equal volumes of a 2 final concentration was added to the wells; the final vehicle (DMSO) concentration did not exceed 0.5%. After incubation, cells were fixed with 3.7% formaldehyde (in PBS) for 1h at room temperature and methanol (100%) permeabilized for 10 min at 20C. Non-specific binding was blocked for 1h with 5% goat serum in PBS buffer containing 0.3% Triton X-100. Cells were then incubated with cleaved caspase-3 (Asp 175) rabbit polyclonal antibody (Cell Signaling Technology, 9661, 1:100 dilution) in 5% goat serum and 0.3% Triton X-100 over night at 4C. Further wash steps removed unbound antibody prior to the addition of the secondary Alexa 488 goat anti-rabbit antibody (Invitrogen, A11034, 10μL/mL) and Hoechst 33342 dye (5 μg/ml) in 5% goat serum and 0.3% triton X-100 for 1 hr at room temperature. The cells were then washed and imaged. For time course experiments, the drug treatment was staggered in hourly intervals and cells were fixed at the end of the experiment.

Images were acquired on the BD Pathway Biomager using the 20/NA 0.75 objective. The system allows great flexibility in the selection of the fluorescent dyes since it uses 2 lamps with broad illumination spectrum and a total choice of 16 excitation filters. Hoechst 33342 (Invitrogen, H3570) and Alexa Fluor images were acquired using standard filter sets for dyes in this range with careful consideration of bleed-through artifacts. The BD Pathway Bioimager also has sophisticated analysis software built in to acquire and analyze images with minimal manual adjustment. Caspase-3 is primarily located in the cytoplasm and the algorithm was set to sample an area around the nucleus as representative of the cytoplasm.

Results

Images acquired by the BD Pathway Bioimager showed a distinct labeling pattern of the activated caspase-3 in response to the apoptosis-inducing drug staurosporine ( Figure 1 ). The doseresponse relationship is highlighted in Figure 1 showing a screen capture of the acquisition software. Each thumbnail image shows a representative area of the sampled well.

The entry into the apoptotic pathway is terminal and once a cell commits, the caspase-3 pathway is completely activated. Therefore, the best measure of the relative apoptotic activity in a well is the percentage of cells above a certain threshold. The BD Image Data Explorer data analysis tool allows setting of multiple thresholds and to plot dose-response curves, calculate EC50 ( Figure 3 ) and Z using these percentages.

Discussion

Activation of the caspase-3 pathway is a hallmark of apoptosis and can be used in cellular assays to quantify activators and inhibitors of the death cascade. The response is both time and concentration dependent suggesting that multiple pathways play a role in triggering the caspase-3 activation. One could hypothesize that cells are most susceptible to staurosporine in a specific phase of the cell cycle and therefore over time, most cells will die, similar to the findings of Vermeulen et. al. (2003).

We show that this representative apoptosis assay can be used in an automated way using the BD Pathway Bioimager and its built-in image and data analysis tools making it amenable to a high-throughput application development. Our data supports findings by Jessel et. al. (2002) who report an EC50 for staurosporine of 200 nM. We specifically see the usefulness of this assay as a building block in a multiplexed high-content assay. This caspase-3 assay can easily be accommodated in a different fluorescence channel and since the BD Pathway Bioimager utilizes broad-spectrum lamps, many dye combinations are possible. The BD Pathway Bioimager and its software tools provide the optimal environment to conduct this kind of multidimensional analysis.

References

1. Jacobson, M.D., Weil, M., Raff, M.C.. 1996. Role of Ced-3/ICE-Family Proteases in Staurospirine-induced Programmed Cell Death. JCB , 133:1041-1051.

2. Lavrik I.N., Golks, A., Krammer, P.H.. 2005. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115:10. 2665-72.

3. Nicholson D.W. Ali A., Thornberry N.A. et al . 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.

4. Vermeulen, K., Berneman, Z.N., Van Bocksaele, D.R. 2003. Cell cycle and apoptosis. Cell Proliferation, 36:165-175.

5. Jessel, R., Haertel, S., Socaciu, C. Tykhonova, S., Diehl, H.A.. (2002). Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J.Cell.Mol.Med. 6. 82-92


'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. Ca++-Induced G Protein Coupled Receptor (GPCR) Activation Monitored via Aequorin Luminescence in the LMax Microplate Luminometer (MaxLine Application Note #42)
3. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
4. Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation
5. RT-PCR Primers for the Study of Apoptosis
6. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
7. Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer
8. Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar
9. An Image-Based Assay of Endothelial Cell Tube Formation as a Model of Angiogenesis
10. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
11. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Caspase Activation Indicator Apoptosis Image Based Assays

(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... UFP Technologies, a producer of ... recently introduced a custom insulated shipping container to ... new insulated shipper solves the issue of temperature ... Technologies’ BioShell is a universal storage container which ... and shipping. The insulated shipper keeps frozen BioShells ...
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
Breaking Biology Technology:The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3Faster Healing with Fewer Scars 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
(Date:9/30/2014)... Having trouble getting pregnanteven with IVF? Here,s some hope: ... of The FASEB Journal , explains ... protein known as PAWP, which induced embryo development in ... of embryo development by the sperm cell during fertilization. ... represent a major paradigm shift in our understanding of ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... varies dramatically according to whether the nurses leave the ... airflow in a "Nightingale" warda classic hospital ward design ... bedsby using tracer gases to simulate how airborne infections ... generally good when windows were left open, keeping the ...
... Male circumcision reduces the abundance of bacteria living on the ... protection against HIV, according to a study led by the ... a significant shift in the bacterial community or microbiome of ... online journal mBio . This international collaboration focused ...
... What do woolly mammoths wandering around the ancient ... do with predicting how species could respond to ... Maryland Center for Environmental Science,s Appalachian Laboratory, along ... the University of California-Merced, have received a three-year, ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3TGen-led study discovers dramatic changes in bacteria following male circumcision 2Scientists look to ancient past to better predict how species may respond climate change 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: